LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

BACKGROUND: Vaccines effectively prevent COVID-19, but some individuals have medical comorbidities or receive therapies that impair their immune response to vaccination, or are ineligible for vaccination. For such individuals who remain at risk of COVID-19, monoclonal antibodies may provide addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Myron J, Ustianowski, Andrew, De Wit, Stéphane, Launay, Odile, Avila, Miles, Seegobin, Seth, Templeton, Alison, Yuan, Yuan, Ambery, Philip, Arends, Rosalinda H, Beavon, Rohini, Near, Karen A, Padilla, Kelly W, Psachoulia, Konstantina, Sharbaugh, Audrey, Streicher, Katie, Pangalos, Menelas N, Esser, Mark T, Gasser, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Late Breaker Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644063/
http://dx.doi.org/10.1093/ofid/ofab466.1646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644063/
http://dx.doi.org/10.1093/ofid/ofab466.1646

Ejemplares similares